Chronic Kidney Disease
Part of NephTimes
Advertisement
Researchers sought to quantify the population at risk for pruritus, clinical determinants, and associated adverse outcomes.
A study assessed whether proton pump inhibitor use accelerated CKD progression and acute kidney injury risk.
Joel Topf spoke with Connie Rhee at SCM25 about her study on cognitive function with dialysis vs conservative CKD management.
A partnership will provide education to primary care clinicians to strengthen identification and treatment of kidney disease.
A study examined the association of ankle-brachial index and CKD progression with type 2 diabetes and elevated BMI.
Could a combined nutritional supplementation and exercise training program improve frailty and health outcomes with CKD?
Is metformin use ever appropriate for patients with advanced kidney disease and type 2 diabetes?
A study compared stroke and dementia risk between race-free and previous eGFR equations.
Researchers estimated tuberculosis incidence and described the disease among the US population with kidney failure.
Furosemide (Furoscix) has been approved by the FDA for the treatment of edema in patients with chronic kidney disease (CKD).
Dietitian Lauren Budd Levy explains the importance of renal nutrition and related sessions at NKF SCM25.
Canagliflozin increased total iron binding capacity and decreased ferritin in patients with type 2 diabetes and CKD.
A study evaluated the effectiveness of spironolactone for reducing adverse cardiovascular outcomes in older adults with CKD.
Researchers studied the efficacy of exercise in improving cognitive function in people with CKD and its potential harm.
A study examined MPS-based gene panel testing in patients with unexplained CKD in a real-world context.
Can lower home systolic BP targets be met in patients with CKD through antihypertensive medications and home BP monitoring?
Research examined the role of serum phosphate in CKD-associated pruritus and the efficacy of treatment with difelikefalin.
Novo Nordisk is suing KBP Biosciences over alleged fraudulent claims about the kidney disease drug ocedurenone.
A team analyzed sotagliflozin's effects on hemoglobin in patients with stage 3-4 CKD and type 2 diabetes.
A study compared the risks of cardiovascular events in hospital settings among patients with CKD with and hyperkalemia.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.